Sale!

SMN1 Gene Spinal Muscular Atrophy Type 4 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The “SMN1 Gene Spinal Muscular Atrophy Type 4 Genetic Test” is a specialized diagnostic procedure available at DNA Labs UAE, aimed at detecting mutations in the SMN1 gene, which are indicative of Spinal Muscular Atrophy (SMA) Type 4. SMA Type 4, also known as adult-onset SMA, is a rare genetic disorder characterized by progressive muscle weakness and atrophy, typically manifesting in adulthood. The test is crucial for individuals with a family history of SMA or those exhibiting symptoms, as it aids in confirming the diagnosis, understanding the disease progression, and making informed decisions about management and care. The test is conducted using a sample of the individual’s DNA, extracted from a blood sample or cheek swab. At DNA Labs UAE, this comprehensive genetic analysis is offered at a cost of 4400 AED, providing invaluable insights into the genetic basis of SMA Type 4 and facilitating early intervention and personalized treatment strategies.

Description

SMN1 Gene Spinal Muscular Atrophy Type 4 Genetic Test

Test Name: SMN1 Gene Spinal Muscular Atrophy Type 4 Genetic Test

Components: Blood or Extracted DNA or One drop Blood on FTA Card

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test Type: Neurological Disorders

Doctor: Neurologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for SMN1 Gene Spinal Muscular Atrophy Type 4 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with SMN1 Gene Spinal Muscular Atrophy Type 4

Test Details:

The SMN1 gene is responsible for producing the survival motor neuron (SMN) protein, which is essential for the survival and function of motor neurons. Spinal muscular atrophy (SMA) is a genetic disorder characterized by the degeneration and loss of motor neurons, leading to muscle weakness and atrophy. There are several types of SMA, with type 4 being the mildest form. It typically manifests in adulthood and is characterized by slowly progressive muscle weakness and atrophy.

Symptoms can vary widely among individuals with SMA type 4, ranging from mild muscle weakness to significant disability. Next-generation sequencing (NGS) is a genetic testing method that allows for the simultaneous analysis of multiple genes, including the SMN1 gene. NGS can identify genetic variants or mutations in the SMN1 gene that may be associated with SMA type 4.

NGS genetic testing for SMA type 4 can provide valuable information for diagnosis, prognosis, and genetic counseling. It can help confirm a clinical suspicion of SMA type 4 and differentiate it from other neuromuscular disorders with similar symptoms. Additionally, NGS can identify carriers of SMN1 gene mutations, which is important for family planning and reproductive decision-making.

Overall, NGS genetic testing for the SMN1 gene in SMA type 4 can provide important genetic information that can aid in the management and understanding of this condition. It is typically performed by specialized laboratories or genetic testing centers.

Test Name	SMN1 Gene Spinal muscular atrophy type 4 Genetic Test
Components
Price	4400.0 AED
Sample Condition	Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery	3 to 4 Weeks
Method	NGS Technology
Test type	Neurological Disorders
Doctor	Neurologist
Test Department:	Genetics
Pre Test Information	Clinical History of Patient who is going for SMN1 Gene Spinal muscular atrophy type 4 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with SMN1 Gene Spinal muscular atrophy type 4
Test Details	The SMN1 gene is responsible for producing the survival motor neuron (SMN) protein, which is essential for the survival and function of motor neurons. Spinal muscular atrophy (SMA) is a genetic disorder characterized by the degeneration and loss of motor neurons, leading to muscle weakness and atrophy. There are several types of SMA, with type 4 being the mildest form. It typically manifests in adulthood and is characterized by slowly progressive muscle weakness and atrophy. Symptoms can vary widely among individuals with SMA type 4, ranging from mild muscle weakness to significant disability. Next-generation sequencing (NGS) is a genetic testing method that allows for the simultaneous analysis of multiple genes, including the SMN1 gene. NGS can identify genetic variants or mutations in the SMN1 gene that may be associated with SMA type 4. NGS genetic testing for SMA type 4 can provide valuable information for diagnosis, prognosis, and genetic counseling. It can help confirm a clinical suspicion of SMA type 4 and differentiate it from other neuromuscular disorders with similar symptoms. Additionally, NGS can identify carriers of SMN1 gene mutations, which is important for family planning and reproductive decision-making. Overall, NGS genetic testing for the SMN1 gene in SMA type 4 can provide important genetic information that can aid in the management and understanding of this condition. It is typically performed by specialized laboratories or genetic testing centers.